Authors

The Potential of Antibody-Drug Conjugates in the Treatment of Breast Cancer

Targeted therapy through the use of antibody–drug conjugates holds great promise for the treatment of many malignancies, in particular, breast cancer.

PRRT Effective and Safe as Salvage Therapy for GEP and Bronchial NETs

Tumor response rates after initial treatment with peptide receptor radionuclide therapy have proven clinical benefit; however, complete response is uncommon.

Emerging Approaches for Gastric/GEJ Cancers Take the Spotlight at ASCO GI

Emerging treatments, particularly claudin 18.2, a potential new biomarker in the HER2-negative gastric and gastroesophageal junction cancer space, were highlights of the 2023 ASCO Gastrointestinal Cancers Symposium.

Consolidation to VRD Improves PFS in Patients With Newly Diagnosed Myeloma

Consolidation therapy with bortezomib/lenalidomide/dexamethasone (VRD) followed by maintenance with lenalidomide until progression or toxicity showed promising results over maintenance alone for patients with transplant-eligible multiple myeloma (NDMM) up to 65 years old, according to a final analysis of the EMN02 trial.

Sipuleucel-T Shows Potential With New Trial Data, But Questions Regarding Clinical Relevance Remain

Since the approval of sipuleucel-T for the treatment of minimally symptomatic metastatic castration-resistant prostate cancer in 2010, barriers to administration and the approval of competing drugs has tampered wide adoption of its use.

Overview of Merkel Cell Carcinoma

Merkel cell carcinoma (MCC) is a rare but potentially lethal skin cancer that has traditionally been treated with surgery, radiation, and in advanced cases, chemotherapy. Patients with even localized disease have a high risk of recurrence and those who develop metastatic disease have had a poor overall survival.

The dtect<em>Dx</em> Breast Test for Breast Cancer

Meredith C. Henderson, PhD, Head, R&D, Provista Diagnostics, describes the dtectDx Breast test.

Dr. Baumann on Hypoxia-Specific PET Imaging in Head and Neck Cancer

Michael Baumann, MD, Professor of Radiation Oncology, Director University of Dresden Cancer Center in Dresden, Germany discusses the DDFMISO-trial, which investigated hypoxia-specific PET imaging during radio-chemotherapy for locally advanced head-and-neck cancer.

Novel Hepatitis C Treatments Impact HCC Care: Q&A With Michael P. Manns, MD

Novel agents that target the replication of the hepatitis C virus are poised to have a far-reaching impact on the prevention and recurrence of hepatocellular carcinoma (HCC).

Case Shows Dramatic Antitumor Effects With Immunotherapy in Melanoma

A letter to the editor in the New England Journal of Medicine from notable researchers at Memorial Sloan Kettering reported a case of complete remission of metastatic melanoma in a patient treated with single doses of ipiliumab and nivolumab.

Dr. Michael Tuttle on Dosimetry Versus Empiric Dosing Radioactive Iodine Treatment

Michael Tuttle, MD, endocrinologist Memorial Sloan Kettering (MSK), discusses best management approaches to radioactive iodine treatment in patients with radioiodine avid distant metastases from differentiated thyroid cancer.

Treatment Strategies to Optimize Outcomes With Brentuximab Vedotin: Management of Common and Rare Toxicities

Common AEs associated with brentuximab vedotin, such as peripheral neuropathy and neutropenia, are often manageable with modifications to dose and schedule.

Conference Marks a Decade of Milestones in HCC

Markers of Excellence

The word &quot;marker&quot; is defined, in medical terms, as &quot;something that serves to identify, predict, or characterize.&quot; A variation on this word, known as a biological marker, or biomarker (defined as a measurable indicator of a biological condition) takes this concept one step further.

Questions Linger Around COVID-19’s Origin

Debate and discussion about the origin of the virus that causes COVID-19 have been at the forefront of the global consciousness since the first cases were reported in December 2019.

Expert Panel Discusses the Financial and Economic Impact of Biosimilars

During a preconference presentation at the Association of Community Cancer Centers 35th National Oncology Conference in Phoenix, a panel of experts discussed the challenges they foresee with the wave of new biosimilar launches expected in 2019.

Immune Checkpoint Inhibitors in Renal Cell Carcinoma

Unspecific immunotherapy with interleukin-2 (IL-2) and interferon-alpha was regarded as the first effective therapy in patients with RCC, leading to remarkable clinical benefit in attaining durable complete responses.

Clinical Findings Identify Associations Between Genomic Correlates and Outcomes in Metastatic CRPC

A study aimed at exploring genomic diversity and defining its associations with clinical outcomes in metastatic castration-resistant prostate cancer found that alterations in&nbsp;RB1&nbsp;were a potent predictor of poor survival and that other common aberrations may serve as prognostic indicators of treatment response, according to recent work published in the&nbsp;Proceedings of the National Academy of Sciences.